CannaMore Biotechs

An innovation R&D platform company for cannabis based drug developments

About Us

CannaMore is a 'Clinical & Pre-Clinical Stage' research company. Committed to the research & development of novel and improved 'Cannabis-Based Solutions'

Advantages

IP BASED PLATFORM

Variety of different IP based Cannabinoid ventures in different fields

STRATEGIC PARTNER

Partners with the largest HMO in Israel + first look right

Multiple Market access

Potential distribution and sales in both long term pharmaceutical and short term wellness

Our Team

David Bassa

Founder & CEO

A leading Experienced and proficient entrepreneur. Main Shareholder in multiple startups. Previously founder of a series of ventures to EXIT in the Hi tech and Biotech industries.

Experienced in Public and Private, Multi Millions & Start Ups companies with extensive experience in business & finance. Ofer has vast experience in fundraising from Angel investors & funds.

Ofer Tsimchi

VP BizDev

A managing partner & co-founder of Danbar Group Ltd., Director at. Serves as the Director at Redhill Biopharma, Maabarot products and many other companies. Served as CEO & chairman at private and publicly traded companies.

Experienced and active executive in multiple startup companies in various Biotech & technologies fields. Graduated B.Sc. in Biology and life science at Tel Aviv University with specialty in biochemistry.

Prof. Moshe Mittelman

Scientific & Medical Consultant

Vast medical experience with an international reputation. Served as Chairman, Department of Medicine and a Hematology Consultant at the Tel Aviv Sourasky (Ichilov) Medical Center. Proficient and experienced with multiple medical and health technologies and fields.

Picture2

Dr. Sari Sagiv, PhD

Senior Scientific Advisor

Over 20 years of proven management experience in the fields of clinical development, business development, marketing and intellectual property from the bio-tech and high-tech industries. The pharma and diagnostics department at Mor Research Applications, the Technology Transfer unit of ‘CLALIT’ Health Services. Holds a PhD in immunology and an MBA from Tel Aviv University.

Picture11

Prof. Moshe Yeshurun, MD

Senior Medical Advisor

Specialist in Internal Medicine, Hematology and Bone Marrow Transplantation. Director of the Bone Marrow Transplantation Unit at Rabin Medical Center, Israel. The inventor of a CBD based drug and IP for treatment of GvHD, sold to publicly traded Kalytera Therapeutics (TSXV: KALY).

Strategic Partner

THE COMPANY'S SHAREHOLDER AND MAIN ACTIVE PARTNER IS MOR RESEARCH APPLICATIONS, THE COMMERCIALIZING ARM OF CLALIT HEALTH SERVICES, THE LARGEST HMO IN ISRAEL.

 

This strategic groundbreaking partnership allows us to enjoy:

  • Proximity to leading research and clinical centers.
  • Direct access to collaboration with leading KOLs and physicians.
  • An insider s look into one of Israel s leading innovation and IP generation centers.

Under Clalit are:

  • over 4.7 M members.
  • operating 14 full scale hospitals.
  • over 2,000 community clinics.
  • over 11,000 employed physicians.
  • Clalit also owns a unique 360 electronic patient database.

Follow us:

© CannaMore Biotechs Ltd. 2018, All Rights Reserved. | Email: Contact@TalentFund.co.il

Scroll to top
Skip to content